ABSTRACT
Chronic hepatitis B (CHB) is an infectious disease characterized by liver damage, which can progress to liver fibrosis, cirrhosis, liver failure or liver cancer, threatening the life of patients. CHB patients are prone to be complicated with hepatitis B virus-associated glomerulonephritis and other kidney diseases, therefore the renal safety should be fully considered in the antiviral treatment of CHB patients. According to current guidelines, telbivudine, entecavir or tenofovir alafenamide are recommended for CHB patients with renal insufficiency or potential renal injury, but each has its advantages and disadvantages. How to carry out antiviral treatment in CHB patients with renal impairment deserves our attention. At the same time, the renal function should be monitored regularly in the course of antiviral treatment to identify the damage of renal function in the early stage. This article reviews the causes of renal dysfunction in CHB patients, the risk of kidney damage during the antiviral treatment, the choices of antiviral therapy and the monitoring of renal function in the patients.
ABSTRACT
Chronic hepatitis B ( CHB), characterized by recurrent liver inflammation caused by hepatitis B virus(HBV), can further develop into decompensated liver cirrhosis ,liver cancer or liver failure. The currently used therapeutic drugs nucleos ( t) ide analogues and interferon can effectively inhibit virus replication, but it is difficult to achieve functional cure ( clinical cure) because of their inability to destroy covalently closed ring DNA ( cccDNA).So we are still facing problems of low HBsAg clearance rate and high recurrence rate after drug withdraw.In recent years, the emerging of new drugs and biological agents provide novel ideas and directions for the functional cure of CHB.This article briefly reviews the new therapeutic methods and strategies for functional cure of CHB.
ABSTRACT
Objective@#To observe the efficacy and safety of de novo combination of Lamivudine(LAM) and Adefovir Dipivoxil (ADV) therapy counter to Entecavir (ETV) monotherapy in patients with chronic hepatitis B (CHB)- related compensated liver cirrhosis.@*Methods@#Patients with chronic hepatitis B-related compensated cirrhosis who were initially treated with LAM and ADV for more than 1 year were randomly assigned to two groups, one half replaced with ETV monotherapy, and the other half continued LAM and ADV co-therapy. Liver biochemistry, renal biochemistry, estimated glomerular filtration rate, alpha-fetoprotein, HBV serology markers and serum HBV DNA were measured every 3 months. Urine β2-microglobulin was measured every 6 months And retinol binding protein, followed up for 3 years. The mean values of the two groups were compared with t-test, and the rate of comparison was analyzed by x2 test.@*Results@#A total of 580 cases were collected, 290 cases were replaced with ETV monotherapy, the other 290 patients continued to LAM and ADV combination therapy. In the ETV group, the rates of HBV DNA negative conversion at 1 year, 2 years and 3 years were 77.6%, 84.5% and 94.5% respectively, while the HBV DNA negative conversion rates at 1, 2 and 3 years in the LAM and ADV combination groups were 69.3%, 73.4% and 80.3% respectively. Among them, the negative rates of HBV DNA in the second year and the third year were P < 0.05, the difference was statistically significant. The 3-year cumulative gene-resistant rate in the ETV group was 1.4%, while the combined treatment was as high as 8.6%, and the difference was statistically significant in the two groups. The estimated value of serum creatinine and glomerular filtration rate in ETV group was followed by 3 years, and the baseline level was maintained, in the same group, the serum creatinine was higher than baseline, and the estimated value of glomerular filtration rate decreased. The results showed that there were 6.2%, 12.1%, 22.1% and 0, 0.3%, 1%, respectively, in 1, 2 and 3 years for the group of consecutive treatment and the replacement of ETV Group. The estimated glomerular filtration rate decreased by more than 30% compared with the baseline. The difference was statistically significant; the proportion of serum creatinine in the 1 year, 2 years and 3 years of the combined treatment group was 1.7%, 4.5% and 6.6%, compared with the baseline rise of > 50 μmol/l, and the ETV group was replaced in the 1 year, The values of 2 and 3 years were 0,0,0.7%, of which the 2nd and 3rd years were statistically significant; the proportion of microalbuminuria and retinol-binding protein in patients with combined treatment group was also significantly higher than that of Β2-m ETV Group.@*Conclusion@#The initial combination of LAM and ADV therapy is inferior in terms of ETV monotherapy. Single therapy with ETV increase the rate of viral response, reduce the incidence of drug resistance, and also reduce the incidence of renal impairment in patients with chronic hepatitis B -related compensated liver cirrhosis.
ABSTRACT
Objective To evaluate the clinical efficacy of interferon(IFN) α-2b,adefovir dipivoxil (ADV),granulocyte-macrophage colony stimulating factor (GM-CSF) and hepatitis B vaccine in the treatment of patients with HBeAg-positive chronic hepatitis B (CHB).Methods Two hundredand forty HBeAg-positive CHB patients admitted in the First Affiliated Hospital,Zhejiang University School of Medicine during November 2013 and December 2015 were retrospectively reviewed.They were randomly assigned to four groups with 60 cases in each group,to receive IFNα-2b (group A),IFNα-2b + ADV (group B),IFNα-2b + ADV + GM-CSF (group C) or IFNoα-2b + ADV + GM-CSF + hepatitis B vaccine (group D) for treatment,respectively.All patients were treated for 48 wks and then followed up for 24 wks.The HBsAg serological response,HBeAg serological response,virological response,biochemical response,histological response and adverse effects were compared among 4 groups.Results After 48-wk treatment,the HBsAg negative conversion rate of group D was significantly higher than that of group A and B (x2 =8.634 and 8.634,both P ＜ 0.01);the seroconversion rate of HBsAg in group D was significantly higher than that in group A and group B (x2 =7.149 and 7.149,both P ＜0.01).The baseline drop rate of HBsAg in group C and D was higher than that in group A (t =4.194 and 4.508,both P ＜0.01).In 24-wk follow-up,HBsAg negative conversion rate was as same as that after 48-wk treatment;the seroconversion rate of HBsAg in group D was significantly higher than that in group A and B (x2 =8.634 and 8.634,both P ＜0.01).The baseline drop rate of HBsAg in group C and group D was higher than that in group A (t =4.546 and 4.969,both P ＜0.01).After 48-wk treatment,the HBeAg negative conversion rate in group D was significantly higher than that in group A (x2 =8.792,P ＜ 0.01);the HBeAg seroconversion rate of group C and D was higher than that of group A (x2 =7.064 and 10.159,P ＜0.01).In 24-wk follow-up,the HBeAg negative conversion rate in group C and D was higher than that in group A (x2 =10.159 and 13.713,P ＜0.01);the HBeAg negative conversion rate in group D was higher than that in group B (x2 =8.155,P ＜0.01);the seroconversion rate of HBeAg in group C and D was higher than that in group A (x2 =10.506 and 12.857,P ＜ 0.01).After 48-wk treatment,the negative rate of HBV DNA in group B,C and D was significantly higher than that in group A (x2 =12.452,17.062 and 20.670,all P ＜0.01).In the 24-wk follow-up,the negative rate of HBV DNA in group B,C and D was also significantly higher than that in group A (x2 =21.121,26.880 and 33.611,all P ＜ 0.01).After 48-wk treatment,the alanine aminotransferase (ALT) normalization rate of the group of C and D was significantly higher than that in group A (x2 =8.711 and 8.711,both P ＜0.01).In the 24-wk follow-up,the ALT normalization rate in group C and D was significantly higher than that in group A (x2 =8.076 and 9.624,P ＜0.01).After 48-wk treatment,the improvement rate of inflammation or fibrosis in the group of A,B and C was significantly higher than that in the group A (x2 =8.543,13.348 and 16.205,all P ＜ 0.01).There were no half-way withdrawal and no serious adverse reactions.The main adverse reactions were fever,headache and fatigue,and no significant difference of above reaction was observed among 4 groups (P ＞ 0.05).Conclusion The new anti-virus/immunoregulation therapy containing IFNα-2b + ADV + GM-CSF + hepatitis B vaccine has a better therapeutic effect for patients with HBeAg-positive CHB.
ABSTRACT
Objective To develop a blood gas,acid-base imbalance analysis computer software to diagnose systematically,rapidly,accurately and automatically determine acid-base imbalance type,and evaluate the clinical application. Methods Using VBA programming language,a computer aided diagnostic software for the judgment of acid-base balance was developed. The clinical data of 220 patients admitted to the Second Affiliated Hospital of Guangzhou Medical University were retrospectively analyzed. The arterial blood gas〔pH value,HCO3-,arterial partial pressure of carbon dioxide(PaCO2)〕and electrolytes included data(Na+and Cl-)were collected. Data were entered into the software for acid-base imbalances judgment. At the same time the data generation was calculated manually by H-H compensation formula for determining the type of acid-base imbalance. The consistency of judgment results from software and manual calculation was evaluated,and the judgment time of two methods was compared. Results The clinical diagnosis of the types of acid-base imbalance for the 220 patients:65 cases were normal,90 cases with simple type,mixed type in 41 cases,and triplex type in 24 cases. The accuracy of the judgment results of the normal and triplex types from computer software compared with which were calculated manually was 100%,the accuracy of the simple type judgment was 98.9% and 78.0% for the mixed type,and the total accuracy was 95.5%. The Kappa value of judgment result from software and manual judgment was 0.935,P=0.000. It was demonstrated that the consistency was very good. The time for software to determine acid-base imbalances was significantly shorter than the manual judgment(seconds:18.14±3.80 vs. 43.79±23.86,t=7.466,P=0.000),so the method of software was much faster than the manual method. Conclusion Software judgment can replace manual judgment with the characteristics of rapid,accurate and convenient,can improve work efficiency and quality of clinical doctors and has great clinical application promotion value.
ABSTRACT
The 210-layer consecutive CT Dicom format image of a healthy human body thoracolumbar was directly reading into the Mimics,and defining bone organization threshold,withdrawing each outline,partitioning each edge of layer picture,selectively editing and repairing by hole processing.After the redundancy data was cleaned,the thoracolumbar 3-D finite element geometry model was acquired.Then area mesh could be introduced into Ansys software directly to compartmentalize mesh body,and then transferred the body mesh to mimics to assignment on the basis of CT values,then add the ligaments and joint-bindings to perfect the 3D finite element model in Ansys.Then bound the lower of L_1 and impose displacement-load in the upper edge of T_(12).The 3D finite element model was reconstructed using CT images from a patient of T_(12) and L_1 vertebral compression fractures.After that,a realistic appearance and calculation accuracy 3-D bone finite element model of thoracolumbar was established.The results showed that reconstructing a three-dimensional finite element model of thoracolumbar spine compression fractures based on fracture mechanism by information from normal human is scientific and effective.
ABSTRACT
Objective:To assess the safety and success of the transradial approach and transfemoral approach for diagnostic cerebral arteriography.Methods:We reviewed the medical records of 153 cerebral angiographic studies were performed by use of a transradial and Transfemoral approach between May 2002 and October 2001. Before transradial procedure,we confirmed the collateral blood supply to the hand from the ulnar artery using a modified Allen test;Before transfemoral procedure,we confirmed impulse of femoral artery.after operations,we analysis X-ray exposure time(min)、constrast medium dose、operative procedure time(min)、angei-complications、self-care ability in 24 hours after operations with statistics. Results:The mean time to initial clinical follow-up was 1.5 months.the difference of age、X-ray exposure time、constrast medium dose、operative procedure time is not statistically significant.However,transradial approach is better than transfemoral approach in angei-complications and self-care ability in 24 hours.Conclusion:Compared with transfemoral and transbrachial approaches. transradial approach for selective Cerebral Angiography is safety、efficacy and less invasive for selective cerebral angiography and may warrant consideration as a standard procedure.
ABSTRACT
<p><b>OBJECTIVE</b>To discuss the roles of serum interleukin-18 (IL-18), interleukin-10 (IL-10) and soluble interleukin-2R (sIL-2R) in the pathogenesis of chronic hepatitis C and to observe the effects of interferon (IFN) on the above- mentioned serum cytokines.</p><p><b>METHODS</b>The levels of above- mentioned cytokines were detected in 10 healthy individuals, 24 asymptomatic hepatitis virus C (HCV) carriers and 27 patients with chronic hepatitis C (before and after IFN treatment) using enzyme linked immunosorbent assay (ELISA).</p><p><b>RESULTS</b>The levels of the cytokines in patients with chronic hepatitis C are higher than in healthy people (P < 0.05) and in asymptomatic HCV carriers (P < 0.05). The values of the cytokines show a significant positive correlation to ALT (P < 0.05). Levels of tested cytokines decreased observably after IFN treatment (P < 0.05). The grades of the serum levels for sIL-2R and IL-10 before IFN treatment (from high to low) were categorized accordingly: non-response group > partial- response group > complete- response group (P < 0.05).</p><p><b>CONCLUSIONS</b>The tested cytokines co-participate in the pathogenesis of chronic hepatitis C, and can be used to evaluate the effect of IFN on the immune state of organisms. Furthermore, sIL-2R and IL-10 are important for predicting the anti-viral efficacy of IFN.</p>